TC |
Stat |
Stk |
Ins |
Fil |
+d |
+w |
+m |
+q |
+h |
+y |
avg |
|---|---|---|---|---|---|---|---|---|---|---|---|
| P | %ret | 2 | 1 | 2 | 5 | 7 | 13 | 19 | -10 | 5 | 6 |
| P | %wins | 100 | 100 | 100 | 100 | 50 | 50 | 83 |
Filing Date |
T Date |
Ticker |
Issuer | Inc | Sector |
Ind | Industry |
Owner |
oSt |
Rel |
Title |
T |
TVal |
Price |
L |
Qty |
oc |
Own |
H |
r2y |
r1y |
r6m |
r3m |
r6w |
r3w |
r7d |
r3d |
f1d |
f1w |
f1m |
f3m |
f6m |
f1y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
4/5/22 08:17 | 4/4/22 | GNCA | Genocea Biosciences, Inc. | DE | Health | BioPrd | Biological Products, (No Diag | Davis Thomas Andrew | MA | O | CHIEF ME | S | -1 | 1.25 | 0 | -1 | -2 | 68 | D | ||||||||||||||
3/17/22 16:09 | 3/16/22 | GNCA | Genocea Biosciences, Inc. | DE | Health | BioPrd | Biological Products, (No Diag | Davis Thomas Andrew | MA | O | CHIEF ME | S.d | -3 | 1.10 | 0 | -3 | -4 | 69 | D | ||||||||||||||
9/17/10 09:15 | 9/16/10 | CLDX | Celldex Therapeutics, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Davis Thomas Andrew | MA | O | SVP,CMO | P | 9 | 3.77 | 3 | 3 | 1 | D | -65 | -31 | -28 | -28 | -27 | -14 | 8 | -5 | 1 | 9 | 23 | 10 | 0 | -28 | |
1/5/06 11:15 | 11/22/05 | GNVC | Genvec Inc | DE | Health | Drug | Pharmaceutical Preparations | Davis Thomas Andrew | X1 | O | Chief Me | P | 9 | 1.82 | 0 | 5 | New | 5 | 9 | 4 | 2 | 27 | -19 | 38 |
| D | Derivative transaction in filing (usually option exercise) |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| A | Amended filing |
| E | Error detected in filing |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |